
ENTX Stock Forecast & Price Target
ENTX Analyst Ratings
Bulls say
Entera Bio Ltd is focused on developing innovative orally delivered macromolecule therapeutics aimed at addressing chronic medical conditions, presenting a strong growth potential given the underserved markets it targets. The recent collaboration with OPKO Health enhances Entera's pipeline by providing access to a promising anti-obesity candidate and advantageous funding terms, which are pivotal for advancing its clinical programs. Positive in vivo pharmacokinetic results for oral formulations not only support the efficacy of Entera's technology but also highlight significant near- and medium-term catalysts that could drive future financial performance.
Bears say
Entera Bio Ltd continues to face significant financial challenges, reporting a net loss of $0.08 per share, primarily driven by higher operating expenses than anticipated. The company is projected to maintain a net loss of $0.05 per share moving forward and will likely require additional capital to support the pivotal clinical development of its lead product candidate, EB613. Furthermore, various risks, including potential delays in clinical advancement and unfavorable market conditions, could impede the company's ability to secure necessary partnerships and achieve successful product commercialization.
This aggregate rating is based on analysts' research of Entera Bio Ltd and is not a guaranteed prediction by Public.com or investment advice.
ENTX Analyst Forecast & Price Prediction
Start investing in ENTX
Order type
Buy in
Order amount
Est. shares
0 shares